adplus-dvertising
Connect with us

Health

UBC biotech spin-off raises $75M to bring cancer treatments to patients

Published

 on

With roots in UBC research, Alpha-9 Theranostics is developing cancer radiotherapies that target tumours while avoiding healthy tissues.

Alpha-9 Theranostics, a UBC spin-off company founded by three university researchers, has raised $75 million to develop next-generation radiopharmaceuticals that promise to meaningfully improve treatment for people with cancer.

Based on more than a decade of ground-breaking research at UBC and BC Cancer, the cancer drugs act like a homing device — seeking out tumours to deliver targeted radiation treatment, while having minimal impact on nearby healthy tissues. This precision targeting results in drugs that can be more effective and have fewer side effects for patients than traditional radiation treatments.

“We founded this company to turn the research we were doing at UBC and BC Cancer into treatments that will help patients thrive and, ultimately, save lives,” says Dr. François Bénard, one of the company’s co-founders, and a radiology professor at UBC’s faculty of medicine and senior executive director of the BC Cancer Research Institute. “Seeing these treatments move into clinical testing following more than a decade of basic and translational research is inspiring and the result of a tremendous collaborative effort. This new financing will further accelerate development, bringing new cancer treatments to patients faster.”

Alpha-9’s radiopharmaceuticals are designed to treat a range of solid and hematologic cancers such as prostate cancer, breast cancer, leukemia and lymphoma. According to Dr. David Hirsch, chief executive officer of Alpha-9, the $75 million in Series B financing will enable the company to bring its first five treatments into clinical trials with patients over the next two years.

“Thanks to the cutting-edge research at UBC, these radiotherapies have tremendous potential to address a wide range of cancers,” says Dr. Hirsch. “In the coming years, we plan to progress multiple treatments into first-in-human clinical trials, harnessing the potential of radiopharmaceuticals to realize more effective treatments for people living with cancer.”

From UBC labs to successful start-up

Alpha-9 was founded in 2019 by Dr. Bénard alongside UBC professors Drs. Kuo-Shyan Lin and David Perrin. But it was a decade earlier that the trio first started working together.

Dr. Perrin, a UBC professor of chemistry, had invented a new method to easily tag molecules with fluorine-18, a radioisotope widely used for cancer imaging. He and Dr. Bénard started exploring how to use this method to label peptides — small molecules that seek out and attach to unique proteins that exist on the surface of tumours — to improve cancer diagnosis.

At the same time, Dr. Lin, a UBC radiology professor and senior scientist at BC Cancer, was developing new cancer-targeting peptides and working with Dr. Bénard to label them with therapeutic radioisotopes. Instead of emitting gamma rays used for imaging, these radioisotopes emit particles, called alpha and beta particles, that destroy cancer cells.

According to Dr. Lin, they each brought unique expertise from their respective disciplines that helped bridge the worlds of cancer diagnostics and therapy.

“Our work was very complimentary and we realized there was tremendous potential to apply it across both the diagnostics and therapeutics spaces. We knew we would need both components, because if we want to do therapy, we also need a diagnostic companion to identify patients who will benefit from therapy,” says Dr. Lin.

Leveraging a team science approach, the researchers began developing peptides that home in on cancer cells, and combining them with diagnostic radioisotopes for cancer localization and treatment planning, and with therapeutic radioisotopes to seek and eliminate cancer cells.

“We founded this company to turn the research we were doing at UBC and BC Cancer into treatments that will help patients thrive and, ultimately, save lives.”
Dr. François Bénard
Professor of Radiology

The researchers filed a number of patents for the technologies they developed and worked with UBC’s University-Industry Liaison Office and the Technology Development Office at BC Cancer to license the technology and eventually form Alpha-9. Dr. Bénard is quick to credit the success to their multi-disciplinary teams, saying that many of the research trainees continue to play a central role in the company today.

“UBC trainees and students were instrumental in the initial research and several have now taken up leadership roles within the company to lead the science,” says Dr. Bénard. “It’s one of the many benefits of doing business in B.C. There are many highly-skilled science trainees that come out of UBC, creating a rich environment for companies to thrive in Vancouver.”

Dr. Julie Rousseau was one of those trainees, working as a postdoctoral fellow in Dr. Bénard’s lab from 2015 to 2019. Now, she’s Alpha-9’s associate director of translational biology.

“During my UBC postdoctoral training with Dr. Bénard, I was trained in preclinical drug screening, target selection, as well as radiopharmaceutical development strategies. I also had the opportunity to hone my mentorship and leadership skills by training undergraduate and graduate trainees within the lab. This exceptional training period has allowed me to assume a leadership role at Alpha-9.”

B.C. a leader in cancer research

Three years after being founded, Alpha-9 has grown to over 15 employees. The company has a research and development facility located in Vancouver as well as offices in Boston.

Alpha-9 plans to leverage the new round of investor financing to continue expanding over the coming year, growing its workforce to as many as 45 employees by the end of 2023. Construction is also underway on a new research facility in the Mount Pleasant area of Vancouver that will house the company’s chemistry, biology, translational research and radiochemistry teams, as well as support product formulation.

According to Dr. Bénard, it’s a testament to B.C.’s established leadership in cancer research.

“Vancouver is home to tremendous experience in radiopharmaceutical development and nuclear medicine that makes it an ideal location for these research labs,” says Dr. Bénard. “There’s a critical mass of expertise that is driving biomedical innovation, in part because of the rich talent and research coming out of UBC, and the broader ecosystem that includes world-leading organizations like BC Cancer and TRIUMF, as well as a range of established and emerging biotech companies.”

For Dr. Dermot Kelleher, dean of UBC’s faculty of medicine and vice-president, health, Alpha-9 is another example of how UBC researchers are driving innovation to tackle today’s most pressing health challenges.

“UBC researchers are accelerating the discovery and development of new treatments for a range of diseases such as cancer, Alzheimer’s and diabetes,” says Dr. Kelleher. “Investors and companies are taking notice of the talent and expertise that exists here and its proximity to the university. They’re increasingly choosing B.C. as a place to invest and grow their business, which is in turn, creating jobs and bringing new treatments to British Columbians sooner.”

Improving patient outcomes

For Dr. Bénard, what’s most exciting about Alpha-9’s rapid growth is the potential to impact patients.

“We’re not talking about 10 or 20 years down the road. There are real short-term objectives to open up multiple clinical trials with patients in the coming years.”

“Thanks to the cutting-edge research at UBC, these radiotherapies have tremendous potential to address a wide range of cancers.”
Dr. David Hirsch
Chief Executive Officer, Alpha-9

Dr. Bénard says that Alpha-9’s new radiopharmaceuticals will add an additional treatment option that is different, yet complementary, to existing approaches. And because the treatments are highly-targeted and designed to avoid healthy tissues, patients undergoing treatment could see fewer side effects and enjoy a greater quality of life.

“Patients are what this is all about. While there have been leaps and bounds in terms of cancer treatment options in recent decades, it remains the leading cause of mortality in Canada. We have a real opportunity to change that and improve outcomes for people living with cancer.”


728x90x4

Source link

Continue Reading

Health

Older patients, non-English speakers more likely to be harmed in hospital: report

Published

 on

 

Patients who are older, don’t speak English, and don’t have a high school education are more likely to experience harm during a hospital stay in Canada, according to new research.

The Canadian Institute for Health Information measured preventableharmful events from 2023 to 2024, such as bed sores and medication errors,experienced by patients who received acute care in hospital.

The research published Thursday shows patients who don’t speak English or French are 30 per cent more likely to experience harm. Patients without a high school education are 20 per cent more likely to endure harm compared to those with higher education levels.

The report also found that patients 85 and older are five times more likely to experience harm during a hospital stay compared to those under 20.

“The goal of this report is to get folks thinking about equity as being a key dimension of the patient safety effort within a hospital,” says Dana Riley, an author of the report and a program lead on CIHI’s population health team.

When a health-care provider and a patient don’t speak the same language, that can result in the administration of a wrong test or procedure, research shows. Similarly, Riley says a lower level of education is associated with a lower level of health literacy, which can result in increased vulnerability to communication errors.

“It’s fairly costly to the patient and it’s costly to the system,” says Riley, noting the average hospital stay for a patient who experiences harm is four times more expensive than the cost of a hospital stay without a harmful event – $42,558 compared to $9,072.

“I think there are a variety of different reasons why we might start to think about patient safety, think about equity, as key interconnected dimensions of health-care quality,” says Riley.

The analysis doesn’t include data on racialized patients because Riley says pan-Canadian data was not available for their research. Data from Quebec and some mental health patients was also excluded due to differences in data collection.

Efforts to reduce patient injuries at one Ontario hospital network appears to have resulted in less harm. Patient falls at Mackenzie Health causing injury are down 40 per cent, pressure injuries have decreased 51 per cent, and central line-associated bloodstream infections, such as IV therapy, have been reduced 34 per cent.

The hospital created a “zero harm” plan in 2019 to reduce errors after a hospital survey revealed low safety scores. They integrated principles used in aviation and nuclear industries, which prioritize safety in complex high-risk environments.

“The premise is first driven by a cultural shift where people feel comfortable actually calling out these events,” says Mackenzie Health President and Chief Executive Officer Altaf Stationwala.

They introduced harm reduction training and daily meetings to discuss risks in the hospital. Mackenzie partnered with virtual interpreters that speak 240 languages and understand medical jargon. Geriatric care nurses serve the nearly 70 per cent of patients over the age of 75, and staff are encouraged to communicate as frequently as possible, and in plain language, says Stationwala.

“What we do in health care is we take control away from patients and families, and what we know is we need to empower patients and families and that ultimately results in better health care.”

This report by The Canadian Press was first published Oct. 17, 2024.

Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

Alberta to launch new primary care agency by next month in health overhaul

Published

 on

 

CALGARY – Alberta’s health minister says a new agency responsible for primary health care should be up and running by next month.

Adriana LaGrange says Primary Care Alberta will work to improve Albertans’ access to primary care providers like family doctors or nurse practitioners, create new models of primary care and increase access to after-hours care through virtual means.

Her announcement comes as the provincial government continues to divide Alberta Health Services into four new agencies.

LaGrange says Alberta Health Services hasn’t been able to focus on primary health care, and has been missing system oversight.

The Alberta government’s dismantling of the health agency is expected to include two more organizations responsible for hospital care and continuing care.

Another new agency, Recovery Alberta, recently took over the mental health and addictions portfolio of Alberta Health Services.

This report by The Canadian Press was first published Oct. 15, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

Experts urge streamlined, more compassionate miscarriage care in Canada

Published

 on

 

Rana Van Tuyl was about 12 weeks pregnant when she got devastating news at her ultrasound appointment in December 2020.

Her fetus’s heartbeat had stopped.

“We were both shattered,” says Van Tuyl, who lives in Nanaimo, B.C., with her partner. Her doctor said she could surgically or medically pass the pregnancy and she chose the medical option, a combination of two drugs taken at home.

“That was the last I heard from our maternity physician, with no further followup,” she says.

But complications followed. She bled for a month and required a surgical procedure to remove pregnancy tissue her body had retained.

Looking back, Van Tuyl says she wishes she had followup care and mental health support as the couple grieved.

Her story is not an anomaly. Miscarriages affect one in five pregnancies in Canada, yet there is often a disconnect between the medical view of early pregnancy loss as something that is easily managed and the reality of the patients’ own traumatizing experiences, according to a paper published Tuesday in the Canadian Medical Association Journal.

An accompanying editorial says it’s time to invest in early pregnancy assessment clinics that can provide proper care during and after a miscarriage, which can have devastating effects.

The editorial and a review of medical literature on early pregnancy loss say patients seeking help in emergency departments often receive “suboptimal” care. Non-critical miscarriage cases drop to the bottom of the triage list, resulting in longer wait times that make patients feel like they are “wasting” health-care providers’ time. Many of those patients are discharged without a followup plan, the editorial says.

But not all miscarriages need to be treated in the emergency room, says Dr. Modupe Tunde-Byass, one of the authors of the literature review and an obstetrician/gynecologist at Toronto’s North York General Hospital.

She says patients should be referred to early pregnancy assessment clinics, which provide compassionate care that accounts for the psychological impact of pregnancy loss – including grief, guilt, anxiety and post-traumatic stress.

But while North York General Hospital and a patchwork of other health-care providers in the country have clinics dedicated to miscarriage care, Tunde-Byass says that’s not widely adopted – and it should be.

She’s been thinking about this gap in the Canadian health-care system for a long time, ever since her medical training almost four decades ago in the United Kingdom, where she says early pregnancy assessment centres are common.

“One of the things that we did at North York was to have a clinic to provide care for our patients, and also to try to bridge that gap,” says Tunde-Byass.

Provincial agency Health Quality Ontario acknowledged in 2019 the need for these services in a list of ways to better manage early pregnancy complications and loss.

“Five years on, little if any progress has been made toward achieving this goal,” Dr. Catherine Varner, an emergency physician, wrote in the CMAJ editorial. “Early pregnancy assessment services remain a pipe dream for many, especially in rural Canada.”

The quality standard released in Ontario did, however, prompt a registered nurse to apply for funding to open an early pregnancy assessment clinic at St. Joseph’s Healthcare Hamilton in 2021.

Jessica Desjardins says that after taking patient referrals from the hospital’s emergency room, the team quickly realized that they would need a bigger space and more people to provide care. The clinic now operates five days a week.

“We’ve been often hearing from our patients that early pregnancy loss and experiencing early pregnancy complications is a really confusing, overwhelming, isolating time for them, and (it) often felt really difficult to know where to go for care and where to get comprehensive, well-rounded care,” she says.

At the Hamilton clinic, Desjardins says patients are brought into a quiet area to talk and make decisions with providers – “not only (from) a physical perspective, but also keeping in mind the psychosocial piece that comes along with loss and the grief that’s a piece of that.”

Ashley Hilliard says attending an early pregnancy assessment clinic at The Ottawa Hospital was the “best case scenario” after the worst case scenario.

In 2020, she was about eight weeks pregnant when her fetus died and she hemorrhaged after taking medication to pass the pregnancy at home.

Shortly after Hilliard was rushed to the emergency room, she was assigned an OB-GYN at an early pregnancy assessment clinic who directed and monitored her care, calling her with blood test results and sending her for ultrasounds when bleeding and cramping persisted.

“That was super helpful to have somebody to go through just that, somebody who does this all the time,” says Hilliard.

“It was really validating.”

This report by The Canadian Press was first published Oct. 15, 2024.

Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.

Source link

Continue Reading

Trending